FDA review of troubled drug could hobble AMAG in proxy fight with activist investor

Amid a proxy fight with an activist investor, AMAG has a message for its shareholders: Don’t worry, we’ve got a plan. But with the FDA potentially pulling a hoped-for prospect off the market, mark another notch in the activists’ belt.